Address
40 Guest St.
Suite 3300
Boston, MA
02135, United States
Contact
Jong Lee+1.617.949.2684
info@dayzerodiagnostics.com
Website
DZD OneSeq
DZD uses proprietary sample prep technology, whole genome sequencing, and machine learning to identify an infection and determine its antibiotic resistance profile in hours rather than days
We offer the only diagnostic working direct from blood (culture-free) to produce both comprehensive ID and AST within hours at the point of care.
- Antimicrobial stewardship
- Microbial diagnostics
- Infection prevention
- Antimicrobial compound/strategy
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Fungi
- Viruses
- Yeasts
- Parasites
Application:
- Human
- Veterinary
- AgriFood
- Environmental
- Other
Development stage:
- Validation
- Research
- Development
- Market entry
- Marketed product
- Company
- Academia
- Institute
- NGO
- Government
Partnering:
- License
- Joint Venture
- Co-develop
- Outsource
- Sell
Funding organisation:
- CARB-X
- OTHER / NA
- FIND
- GARDP
- REPAIR
Infectious disease area:
- BSI
- UTI
- STI
- RTI
- GII
- SSTI
- CNSI
- IAI
- SSI
Geographic origin:
- North America
- South America
- Eurasia
- Africa
- Oceania
We welcome partnership discussions exploring data and technology licensing opportunities, as well as co-development of infectious disease diagnostic solutions.
Day Zero Diagnostics is revolutionizing infectious disease diagnosis and treatment with genomic sequencing and machine learning to solve antibiotic resistance.
Customers of our diagnostic will also be get access to services that utilize the data from the diagnostic to identify hospital acquired infections, provide regional information on rare and unusual strains, and forecast operational needs.
